Bryn Mawr Trust CO Summit Therapeutics Inc. Transaction History
Bryn Mawr Trust CO
- $5.88 Billion
- Q3 2025
A detailed history of Bryn Mawr Trust CO transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 120 shares of SMMT stock, worth $2,245. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120Holding current value
$2,245% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
270Shares Held
90.8MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$631 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$162 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$148 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$75.2 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$73.1 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.76B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...